多奈单抗治疗与早期症状性阿尔茨海默病探索性血浆生物标志物的关联:TRAILBLAZER-ALZ随机临床试验的二次分析
TRAILBLAZER-ALZ是一项随机双盲安慰剂对照试验,纳入272例早期症状性阿尔茨海默病患者,比较多奈单抗与安慰剂对血浆生物标志物的影响。结果显示多奈单抗组血浆pTau217和GFAP水平较安慰剂组显著降低,且与淀粉样蛋白Centiloid百分比变化相关。
要点
- 多奈单抗组血浆pTau217较安慰剂组显著降低,差异为-0.04(95%CI -0.07至-0.02),P=0.002。
- 多奈单抗组血浆GFAP较安慰剂组显著降低,差异为-0.04(95%CI -0.07至-0.01),P=0.01。
- 血浆pTau217和GFAP变化与淀粉样蛋白Centiloid百分比变化显著相关。
核心结论
- 早期症状性阿尔茨海默病患者接受多奈单抗治疗后,血浆pTau217和GFAP较安慰剂显著降低。
- 这些易获取的血浆生物标志物可能为抗淀粉样蛋白治疗导致的阿尔茨海默病病理改变提供额外证据。
- 其在评估治疗反应中的 usefulness 仍需进一步评估。
研究设计与样本
- TRAILBLAZER-ALZ为随机双盲安慰剂对照临床试验,于2017年12月18日至2020年12月4日在美国和加拿大56个中心开展。
- 共272例参与者被随机分组,平均(SD)年龄75.2(5.5)岁,145例(53.3%)为女性。
- 纳入60至85岁、记忆功能逐渐进展性改变至少6个月、简易精神状态检查评分20至28分且淀粉样蛋白升高、tau水平中等的患者。
- 随机参与者每4周接受多奈单抗或安慰剂治疗,最长72周;多奈单抗前3剂为700 mg,随后增至1400 mg,并根据淀粉样蛋白减少情况设盲法剂量下调。
主要发现
- 治疗开始后仅12周时,多奈单抗组血浆pTau217较安慰剂组显著降低,最小二乘均值变化差异为-0.04(95%CI -0.07至-0.02),P=0.002。
- 治疗开始后仅12周时,多奈单抗组血浆GFAP较安慰剂组显著降低,最小二乘均值变化差异为-0.04(95%CI -0.07至-0.01),P=0.01。
- 治疗结束时,两组间血浆淀粉样蛋白β42/40和神经丝轻链水平未见显著差异。
- 血浆pTau217变化与淀粉样蛋白Centiloid百分比变化显著相关,Spearman秩相关系数R=0.484(95%CI 0.359-0.592),P<0.001。
- 血浆GFAP变化与淀粉样蛋白Centiloid百分比变化显著相关,R=0.453(95%CI 0.306-0.579),P<0.001。
关键数值与推荐
- 血浆pTau217和GFAP在多奈单抗组较安慰剂组显著降低,差异分别为-0.04(95%CI -0.07至-0.02;P=0.002)和-0.04(95%CI -0.07至-0.01;P=0.01)。
- 血浆pTau217和GFAP变化与淀粉样蛋白Centiloid百分比变化的相关系数分别为R=0.484(95%CI 0.359-0.592;P<0.001)和R=0.453(95%CI 0.306-0.579;P<0.001)。
- 基线及治疗后血浆pTau217与GFAP水平均显著相关,R=0.399(95%CI 0.278-0.508;P<0.001)和R=0.393(95%CI 0.254-0.517;P<0.001)。
临床怎么用
- 这些易获取的血浆生物标志物可能为抗淀粉样蛋白治疗导致的阿尔茨海默病病理改变提供额外证据。
- 其在评估治疗反应中的 usefulness 仍需进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes. OBJECTIVE: To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: TRAILBLAZER-ALZ was a randomized, double-blind, placebo-controlled clinical trial conducted from December 18, 2017, to December 4, 2020, across 56 sites in the US and Canada. Exploratory biomarkers were prespecified with the post hoc addition of plasma glial fibrillary acidic protein and amyloid-β. Men and women aged 60 to 85 years with gradual and progressive change in memory function for at least 6 months were included. A total of 1955 participants were assessed for eligibility. Key eligibility criteria include Mini-Mental State Examination scores of 20 to 28 and elevated amyloid and intermediate tau levels. INTERVENTIONS: Randomized participants received donanemab or placebo every 4 weeks for up to 72 weeks. The first 3 doses of donanemab were given at 700 mg and then increased to 1400 mg with blinded dose reductions as specified based on amyloid reduction. MAIN OUTCOMES AND MEASURES: Change in plasma biomarker levels after donanemab treatment. RESULTS: In TRAILBLAZER-ALZ, 272 participants (mean [SD] age, 75.2 [5.5] years; 145 [53.3%] female) were randomized. Plasma levels of phosphorylated tau217 (pTau217) and glial fibrillary acidic protein were significantly lower with donanemab treatment compared with placebo as early as 12 weeks after the start of treatment (least square mean change difference vs placebo, -0.04 [95% CI, -0.07 to -0.02]; P = .002 and -0.04 [95% CI, -0.07 to -0.01]; P = .01, respectively). No significant differences in plasma levels of amyloid-β 42/40 and neurofilament light chain were observed between treatment arms at the end of treatment. Changes in plasma pTau217 and glial fibrillary acidic protein were significantly correlated with the Centiloid percent change in amyloid (Spearman rank correlation coefficient [R] = 0.484 [95% CI, 0.359-0.592]; P < .001 and R = 0.453 [95% CI, 0.306-0.579]; P < .001, respectively) following treatment. Additionally, plasma levels of pTau217 and glial fibrillary acidic protein were significantly correlated at baseline and following treatment (R = 0.399 [95% CI, 0.278-0.508], P < .001 and R = 0.393 [95% CI, 0.254-0.517]; P < .001, respectively). CONCLUSIONS AND RELEVANCE: Significant reductions in plasma biomarkers pTau217 and glial fibrillary acidic protein compared with placebo were observed following donanemab treatment in patients with early symptomatic Alzheimer disease. These easily accessible plasma biomarkers might provide additional evidence of Alzheimer disease pathology change through anti-amyloid therapy. Usefulness in assessing treatment response will require further evaluation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03367403.
引用
- Pontecorvo MJ, Lu M, Burnham SC, et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 36251300. doi:10.1001/jamaneurol.2022.3392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。